IP Library Granted Patent US 10,647,716
Granted Patent B2
US 10,647,716 · App. 16/441,610 · Granted May 12, 2020

Heterocyclic compounds and uses thereof

Inventors: Prabha N. Ibrahim (Mountain View, CA); Wayne Spevak (Berkeley, CA); Jiazhong Zhang (Foster City, CA); Songyuan Shi (Fremont, CA); Ben Powell (Pleasant Hill, CA); Yan Ma (Belmont, CA)
Assignee: Plexxikon Inc.
C07D471/04A61K31/444A61K31/5377
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,647,716
App. No.
16/441,610
Granted
May 12, 2020
Kind
B2
Abstract

Provided herein are heterocyclic compounds of Formula (I), pharmaceutical compositions containing such a compound and their therapeutic uses, methods for their preparation, intermediate compounds, pharmaceutical compositions containing such a compound, and their therapeutic uses.

Claims (15)

1. A process of making compound 13:

said process comprising contacting compound 12:

with potassium tert-butoxide and iodomethane under conditions sufficient to form compound 13.

2. A process of making compound P-002:

said process comprising contacting compound 13:

with compound 13b:

in the presence of [1,1′-Bis(diphenyl-phosphino)ferrocene]dichloropalladium(II) under conditions sufficient to form compound P-002.

3. A process of making a compound P-001:

said process comprising contacting compound P-002:

with lithium hydroxide under conditions sufficient to form compound P-001.

4. A compound of formula:

5. A method for treating acute myeloid leukemia comprising administering to a subject in need thereof an effective amount of a compound of formula:

or a pharmaceutically acceptable salt thereof, and azacitidine.

6. A method for treating ovarian cancer comprising administering to a subject in need thereof an effective amount of a compound of formula:

or a pharmaceutically acceptable salt thereof, and carboplatin.

Assignments (5)
CORRECTIVE ASSIGNMENT TO CORRECT THE 16TH PATENT NUMBER PREVIOUSLY RECORDED AT REEL: 062856 FRAME: 0846. ASSIGNOR(S) HEREBY CONFIRMS THE CHANGE OF NAME. Recorded Mar 28, 2023
From: OPNA IMMUNO-ONCOLOGY SA
To: OPNA BIO SA
Reel/Frame 063588/0355 →
CHANGE OF NAME Recorded Mar 2, 2023
From: OPNA IMMUNO-ONCOLOGY SA
To: OPNA BIO SA
Reel/Frame 062856/0846 →
CORRECTION OF AN ERROR IN ASSIGNOR'S NAME IN A COVER SHEET PREVIOUSLY RECORDED AT REEL 059925 FRAME 0772. Recorded May 20, 2022
From: PLEXXIKON INC.
To: OPNA IMMUNO-ONCOLOGY SA
Reel/Frame 060131/0148 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 10, 2022
From: PLEXXICON INC.
To: OPNA IMMUNO-ONCOLOGY SA
Reel/Frame 059925/0772 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 30, 2019
From: IBRAHIM, PRABHA N.; SPEVAK, WAYNE; ZHANG, JIAZHONG; SHI, SONGYUAN; POWELL, BEN; MA, YAN
To: PLEXXIKON INC.
Reel/Frame 050226/0784 →
Cited By (1)
US 12,509,444